Codeine

A landmark University of Sydney review reveals opioids often offer minimal, short-lived acute pain relief, performing no better than placebo for many conditions. This challenges established prescribing norms for molecules like codeine and oxycodone, necessitating immediate strategic re-evaluation for pharmaceutical manufacturers, procurement, and regulatory affairs globally, driving a critical shift towards non-opioid alternatives and revised clinical guidelines.